Moreover, it has recently been shown that the DR5 agonistic antibody lexatumumab robustly suppresses lymph node or lung metastasis in an orthotopic model of triple-negative breast cancer [21]. This evidence concerns the gene TNFRSF10B and triple-negative breast carcinoma.